

## NOXXON ANNOUNCES AMENDMENT TO LOAN AGREEMENTS

**Berlin, Germany, July 16, 2018, 06.00 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX)**, a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has amended the existing agreements with Kreos Capital ([see 2017 Annual Report](#) for further details) extending from September 30, 2018 until June 30, 2019, the time during which Kreos Capital will not request the redemption of and interest payment on its outstanding debt, and during which qualifying equity raises will result in conversion of the remaining debt to ordinary shares of the company.

**For more information, please contact:**

**NOXXON Pharma N.V.**

Aram Mangasarian, Ph.D., Chief Executive Officer  
Tel. +49 (0) 30 726 247 0  
[amangasarian@noxxon.com](mailto:amangasarian@noxxon.com)

**MC Services AG**

Raimund Gabriel, Managing Partner  
Tel. +49 (0) 89 210228 0  
[noxxon@mc-services.eu](mailto:noxxon@mc-services.eu)

**Trophic Communications**

Gretchen Schweitzer or Joanne Tudorica  
Tel. +49 (0) 89 2388 7730 or +49 (0) 172 861 8540  
[schweitzer@trophic.eu](mailto:schweitzer@trophic.eu)

**NewCap**

Alexia Faure  
Tel. +33 (0) 1 44 71 98 51  
[afaure@newcap.fr](mailto:afaure@newcap.fr)

**About NOXXON**

NOXXON's oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor microenvironment, NOXXON's approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. The company plans to initiate further studies with NOX-A12 in brain cancer in combination with radiotherapy, for which an orphan drug status has been granted in the US and EU. The company's second asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in pancreatic cancer patients both as a monotherapy and in combination. Further information can be found at: [www.noxxon.com](http://www.noxxon.com)

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.



<https://www.linkedin.com/company/noxxon-pharma-ag>



[https://twitter.com/noxxon\\_pharma](https://twitter.com/noxxon_pharma)

## **Disclaimer**

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.